DP₂ receptor antagonists in development

Bibliography

• Wenzel SE, Westcott JY, Smith HR, Larsen GL. Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am Rev Respir Dis 1989;139(2):450-7
   PubMed Web of Science ®Google Scholar
• Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46(2):205-29
   PubMed Web of Science ®Google Scholar
• Hirai H, Tanaka K, Yoshie O, Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193(2):255-61
   PubMed Web of Science ®Google Scholar
• Sawyer N, Cauchon E, Chateauneuf A, Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol 2002;137(8):1163-72
   PubMed Web of Science ®Google Scholar
• Mckenniff MG, Rodger IW, Norman P, Gardiner PJ. Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways. Eur J Pharmacol 1988;153(2-3):149-59
   PubMed Web of Science ®Google Scholar
• Mckenniff MG, Norman P, Cuthbert NJ, Gardiner PJ. BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro. Br J Pharmacol 1991;104(3):585-90
   PubMed Web of Science ®Google Scholar
• Magnussen H, Boerger S, Templin K, Baunack AR. Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1992;89(6):1119-26
   PubMed Web of Science ®Google Scholar
• Johnston SL, Smith S, Harrison J, The effect of BAY u 3405, a thromboxane receptor antagonist, on prostaglandin D2-induced nasal blockage. J Allergy Clin Immunol 1993;91(4):903-9
   PubMed Web of Science ®Google Scholar
• Johnston SL, Freezer NJ, Ritter W, Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. Eur Respir J 1995;8(3):411-15
   PubMed Web of Science ®Google Scholar
• Terada N, Yamakoshi T, Hasegawa M, A. The effect of ramatroban (BAY u 3405), a thromboxane A2 receptor antagonist, on nasal cavity volume and minimum cross-sectional area and nasal mucosal hemodynamics after nasal mucosal allergen challenge in patients with perennial allergic rhinitis. Acta Otolaryngol Suppl 1998;537:32-7
   PubMedGoogle Scholar
• Sugimoto H, Shichijo M, Iino T, An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 2003;305(1):347-52
   PubMed Web of Science ®Google Scholar
• Hata AN, Lybrand TP, Marnett LJ, Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol 2005;67:640-7
   PubMed Web of Science ®Google Scholar
• Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007;6(4):313-25
   PubMed Web of Science ®Google Scholar
• Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol 2008;153(Suppl 1):S191-9
   PubMed Web of Science ®Google Scholar
• Philip G, van Adelsberg J, Loeys T, Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol 2009;124(5):942-8
   PubMed Web of Science ®Google Scholar
• Birkinshaw TN, Teague SJ, Beech C, Discovery of potent CRTh2 (DP2) receptor antagonists. Bioorg Med Chem Lett 2006;16(16):4287-90
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. Novel process for the preparation of substituted indoles. WO2006075139; 2006
   Google Scholar
• AstraZeneca. One Month Dose Response Study of AZD1981 in asthma patients uncontrolled on inhaled steroids (OLIVE). NCT00758589
   Google Scholar
• AstraZeneca. 14729-D9831C00002- 1 Month Biopsy Study. NCT00766415
   Google Scholar
• Sargnet C, Stinson S, Schmidt J, The effect of a selective CRTh2 antagonist on tobacco smoke (TS) induced airway inflammation and remodelling in the mouse. Br J Pharmacol 2009;98. Available from: https://bps.conference-services.net/resources/344/1686/pdf/JB2009_0098.pdf
   Google Scholar
• AstraZeneca AB. Novel compounds 951: a biphenyloxypropanoic acid as CRTH2 modulator and intermediates. WO2009004379
   Google Scholar
• Oxagen plc. Available from: http://www.oxagen.co.uk/pdfs/CRTH2summary.pdf
   Google Scholar
• Armer RE, Ashton MR, Boyd EA, Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2. J Med Chem 2005;48(20):6174-7
   PubMed Web of Science ®Google Scholar
• Oxagen Ltd. Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid. WO2006092579; 2006
   Google Scholar
• Stearns BA, Baccei C, Bain G, Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis. Bioorg Med Chem Lett 2009;19(16):4647-51
   PubMed Web of Science ®Google Scholar
• Oxagen Ltd. Compounds having CRTH2 antagonist activity. WO2008012511; 2008
   Google Scholar
• Pettipher R, Hansel TT. Antagonists of the prostaglandin D2 receptor CRTH2. Drug News Perspect 2008;21(6):317-322
   PubMed Web of Science ®Google Scholar
• Pettipher R. Role of CRTH2 in promoting Th2-mediated allergic responses New Drugs and Targets for Asthma and COPD, National Heart and Lung Institute, November 2008. Available from: (http://www.oxagen.co.uk/pdfs/NHLI%20November%2020%202008.pdf)
   Google Scholar
• Oxagen Ltd. Novel CRTH2 antagonist shows potential in moderate persistent asthma: presented at ERS 18 September 2009. Available from: http://main.pslgroup.com/news/content.nsf/medicalnews/852576140048867A8525 7635005BC1C3?OpenDocument&id=&count=10
   Google Scholar
• Oxagen OC000459 Dose Finding Study in patients with mild to moderate persistent asthma. NCT00890877
   Google Scholar
• Fecher A, Pothier J, Gude M, Novel Classes Of Crth2 Receptor Antagonists AFMC International Medicinal Chemistry Symposium 2008; XXth:September 02 (P227)
   Google Scholar
• Actelion Pharmaceuticals Ltd. (3-Amino-1,2,3,4-tetrahydro-9h- carbazol-9-yl)-acetic acid derivatives. WO2008017989; 2008
   Google Scholar
• Actelion Pharmaceuticals Ltd. Tetrahydropyridoindole derivatives. WO2005095397; 2009
   Google Scholar
• Arimura A, Yasui K, Kishino J, Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 2001;298(2):411-19
   PubMed Web of Science ®Google Scholar
• Arimura A. Discovery of a first-in-class drug, a prostaglandin D2 antagonist, for the treatment of allergic disease. In: Tamaki N, Kuge Y, editors, Molecular imaging for integrated medical therapy and drug development. Springer, Japan; 2010. p.281-7
   Google Scholar
• Shionogi & Co., Ltd. Method for producing N-phenyl-N'-phenylsulfonylpiperazine derivative. WO-2008123349; 2008
   Google Scholar
• Amira Pharmaceuticals, Inc. Antagonists of PGD2 receptors. WO2009061676; 2009
   Google Scholar
• Amira Pharmaceuticals, Inc. Antagonists of prostaglandin D2 receptors. WO2009108720; 2009
   Google Scholar
• Stebbins K, Broadhead AR, Baccei CS, Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia and epithelial hyperplasia in the mouselLung. J Pharmacol Exp Ther 2010;332(3):764-75
   PubMed Web of Science ®Google Scholar
• Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist. WO2008156780; 2008
   Google Scholar
• Actimis Pharmaceuticals, Inc. Amine salts of a CRTH2 antagonist. WO2008156781; 2008
   Google Scholar
• Actimis Pharmaceuticals, Inc. Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2. WO2004096777; 2004
   Google Scholar
• Boehme SA, Franz-Bacon K, Chen EP, A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol 2009;21(1):81-93
   PubMed Web of Science ®Google Scholar
• Liu J, Fu Z, Wang Y, Discovery and optimization of CRTH2 and DP dual antagonists. Bioorg Med Chem Lett 2009;19(22):6419-23
   PubMed Web of Science ®Google Scholar
• Amgen, Inc. Phenyl acetic acid derivatives as inflammation modulators. WO2009085177; 2009
   Google Scholar
• Liu J, Wang Y, Sun Y, Tetrahydroquinoline derivatives as CRTH2 antagonists. Bioorg Med Chem Lett 2009;19(24):6840-4
   PubMed Web of Science ®Google Scholar
• Ulven T, Kostenis E. Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem 2005;48(4):897-900
   PubMed Web of Science ®Google Scholar
• Mathiesen JM, Christopoulos A, Ulven T, On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2. Mol Pharmacol 2006;69(4):1441-53
   PubMed Web of Science ®Google Scholar
• Uller L, Mathiesen JM, Alenmyr L, Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res 2007;8:16
   PubMed Web of Science ®Google Scholar
• Grimstrup M, Rist O, Receveur JM, Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2. Bioorg Med Chem Lett 2010;20(3):1181-5
   PubMed Web of Science ®Google Scholar
• Grimstrup M, Receveur JM, Rist O, Exploration of SAR features by modifications of thiazoleacetic acids as CRTH2 antagonists. Bioorg Med Chem Lett 2010;20(5):1638-41
   PubMed Web of Science ®Google Scholar
• Argenta Discovery Ltd. Indolizine derivatives as ligands of the CRTH2 receptor. WO2007031747; 2007
   Google Scholar
• Argenta Annual Report; 2008
   Google Scholar
• sanofi-aventis. A new process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl}-phenyl)- 2-methylpropionic acid. WO2009006086; 2009
   Google Scholar
• Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases. WO2006091674; 2006
   Google Scholar
• Mimura H, Ikemura T, Kotera O, Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2. J Pharmacol Exp Ther 2005;314(1):244-51
   PubMed Web of Science ®Google Scholar
• Array Biopharma, Inc. 4-Heteroaryl-substituted phenoxyphenylacetic acid. WO2009061730; 2009
   Google Scholar
• Eberhardt C, Wright D, Gomez A, Identification and characterization of a potent and selective antagonist of the prostaglandin D2 receptor. Available from: http://www.arraybiopharma.com/_documents/Publication/PubAttachment342.pdf
   Google Scholar
• Shiraishi Y, Burgess LE, Takeda K, PGD2 enhances and CRTH2 antagonism prevents early- and late-phase responses in allergic rhinitis. Available from: http://www.arraybiopharma.com/_documents/Publication/PubAttachment345.pdf
   Google Scholar
• Novartis AG. Use of pyrrolo[2,3-b] pyridines to prepare a medicament for treating pain. WO2007068418; 2007
   Google Scholar
• Sandham DA, Aldcroft C, Baettig U, 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett 2007;17(15):4347-50
   PubMed Web of Science ®Google Scholar
• Sandham DA, Adcock C, Bala K, 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists. Bioorg Med Chem Lett 2009;19(16):4794-8
   PubMed Web of Science ®Google Scholar
• Crosignani S, Page P, Missotten M, Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J Med Chem 2008;51(7):2227-43
   PubMed Web of Science ®Google Scholar
• Astellas Pharma, Inc. Carboxylic acid compound or salt thereof. WO2009096526; 2009
   Google Scholar
• Abbott Laboratories. Thienopyrroles and pyrrolothiazoles as new therapeutic agents. WO2009102462; 2009
   Google Scholar
• Ligand Pharmaceuticals, Inc. 2-Phenyl phenoxyacetic acids useful for treating inflammatory disorders. WO2009089192; 2009
   Google Scholar
• Chemietek Llc. Heterocyclic compounds as CRTH2 receptor antagonists. WO2009049021; 2009
   Google Scholar
• Icos Corp. Substituted phenyl acetic acids as DP-2 antagonists. WO2007143745; 2007
   Google Scholar
• Merck Frosst Canada Ltd. Indole derivatives as CRTH2 receptor antagonists. WO2007019675; 2007
   Google Scholar
• Tumey LN, Robarge MJ, Gleason E, 3-Indolyl sultams as selective CRTh2 antagonists. Bioorg Med Chem Lett 2010;20(11):3287-90
   PubMed Web of Science ®Google Scholar
• Atherysys, Inc. Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof. WO2006034419; 2006
   Google Scholar
• Ly TW, Bacon KB. Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview. Expert Opin Investig Drugs 2005;14(7):769-73
   PubMed Web of Science ®Google Scholar
• Jones RL, Giembycz MA, Woodward DF. Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 2009;158(1):104-45
   PubMed Web of Science ®Google Scholar